NCT04097210

Brief Summary

Patients with degreased (DGC) for ambiguous reasons receive low triage priority. Their death risk is triple. Tools are needed to identify the critically ill patients from this group. The triage used today is not effective. The bedside point-of-care measurements are CRP, lactate acid and suPAR (Soluble Urokinase Plasminogen Activator Receptor). Elevated values associate with the probability of critical illness and predict a risk of death.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2016

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

November 26, 2018

Completed
10 months until next milestone

First Posted

Study publicly available on registry

September 20, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

January 31, 2022

Status Verified

November 1, 2018

Enrollment Period

5.4 years

First QC Date

November 26, 2018

Last Update Submit

January 28, 2022

Conditions

Critical Illness

Keywords

Q-CRPlactatesuPARPOCambulance

Outcome Measures

Primary Outcomes (1)

  • Number of patients with high suPAR level

    A high suPAR level, e.g. above 6 ng/ml

    24 hours

Interventions

POCDIAGNOSTIC_TEST

Eligibility Criteria

Age16 Years - 104 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with degreased condition (DGC) over 18 years who exhibit non-specific symptoms and transported to the emergency room.

You may qualify if:

  • Patients over 18 years who exhibit non-specific symptoms and transported to the emergency room.

You may not qualify if:

  • Abnormal vitals

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

No biospecimen banking

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Maaret Castrén, Professor

    Helsinki University Central Hospital

    STUDY DIRECTOR

  • Johanna Kaartinen, PhD

    Helsinki University Central Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, principal investigator

Study Record Dates

First Submitted

November 26, 2018

First Posted

September 20, 2019

Study Start

January 1, 2016

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

January 31, 2022

Record last verified: 2018-11